Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Emergent BioSolutions Announces Stock Repurchase Program
08:00am, Monday, 31'st Mar 2025
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the compa
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
04:30pm, Thursday, 20'th Mar 2025
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across th
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
08:06am, Thursday, 20'th Mar 2025
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch ef
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
04:30pm, Wednesday, 19'th Mar 2025
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facilit
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for deli
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring wide
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
09:14am, Monday, 10'th Mar 2025
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufactu
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript
07:58pm, Monday, 03'rd Mar 2025
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Offi
Emergent Biosolutions (EBS) Q4 Earnings Top Estimates
06:40pm, Monday, 03'rd Mar 2025
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
04:23pm, Monday, 03'rd Mar 2025
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024.
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
08:55am, Tuesday, 18'th Feb 2025
Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 Separately, Company leaders will attend and present at J.P. Morgan's 2025 Le
GAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro foot
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
08:00am, Thursday, 16'th Jan 2025
Africa CDC's support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.
Emergent BioSolutions: Stock Is A Likely Winner In 2025
07:53am, Tuesday, 14'th Jan 2025
Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The
